Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ultragenyx Pharmaceutical...

    NASDAQ: RARE · Real-Time Price · USD
    37.03
    -0.46 (-1.23%)
    At close: Jun 16, 2025, 3:59 PM
    37.11
    0.22%
    After-hours: Jun 16, 2025, 04:20 PM EDT

    Ultragenyx Pharmaceutical Statistics

    Share Statistics

    Ultragenyx Pharmaceutical has 94.54M shares outstanding. The number of shares has increased by 2.13% in one year.

    Shares Outstanding

    n/a
    		 94.54M

    Shares Change (YoY)

    n/a
    		 2.13%

    Shares Change (QoQ)

    n/a
    		 0.17%

    Owned by Institutions (%)

    n/a
    		 91.63%

    Shares Floating

    n/a
    		 88.37M

    Failed to Deliver (FTD) Shares

    n/a
    		 18

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 5.55M, so 5.87% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.55M

    Short % of Shares Out

    n/a
    		 5.87%

    Short % of Float

    n/a
    		 6.08%

    Short Ratio (days to cover)

    n/a
    		 5.53

    Valuation Ratios

    The PE ratio is -6.69 and the forward PE ratio is -11.23. Ultragenyx Pharmaceutical's PEG ratio is 0.28.

    PE Ratio

    n/a
    		 -6.69

    Forward PE

    n/a
    		 -11.23

    PS Ratio

    n/a
    		 6.8

    Forward PS

    n/a
    		 1.4

    PB Ratio

    n/a
    		 14.92

    P/FCF Ratio

    n/a
    		 -9.03

    PEG Ratio

    n/a
    		 0.28
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Ultragenyx Pharmaceutical.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.16.

    Current Ratio

    n/a
    		 2.37

    Quick Ratio

    n/a
    		 2.24

    Debt / Equity

    n/a
    		 0.16

    Debt / EBITDA

    n/a
    		 -0.09

    Debt / FCF

    n/a
    		 -0.1

    Interest Coverage

    n/a
    		 -8.5

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $432,944.36

    Profits Per Employee

    n/a
    		 $-439,863.21

    Employee Count

    n/a
    		 1,294

    Asset Turnover

    n/a
    		 0.37

    Inventory Turnover

    n/a
    		 1.7

    Taxes

    Income Tax

    n/a
    		 1.6M

    Effective Tax Rate

    n/a
    		 -0.28%

    Stock Price Statistics

    The stock price has increased by -6.96% in the last 52 weeks. The beta is 0.24, so Ultragenyx Pharmaceutical's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.24

    52-Week Price Change

    n/a
    		 -6.96%

    50-Day Moving Average

    n/a
    		 35.97

    200-Day Moving Average

    n/a
    		 44.42

    Relative Strength Index (RSI)

    n/a
    		 52.37

    Average Volume (20 Days)

    n/a
    		 995,823

    Income Statement

    In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.

    Revenue

    n/a
    		 560.23M

    Gross Profit

    n/a
    		 483.5M

    Operating Income

    n/a
    		 -535.97M

    Net Income

    n/a
    		 -569.18M

    EBITDA

    n/a
    		 -469M

    EBIT

    n/a
    		 -504.55M

    Earnings Per Share (EPS)

    n/a
    		 -6.29
    Full Income Statement

    Balance Sheet

    The company has 173.73M in cash and 40.34M in debt, giving a net cash position of 133.39M.

    Cash & Cash Equivalents

    n/a
    		 173.73M

    Total Debt

    n/a
    		 40.34M

    Net Cash

    n/a
    		 133.39M

    Retained Earnings

    n/a
    		 -3.96B

    Total Assets

    n/a
    		 1.31B

    Working Capital

    n/a
    		 407.49M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -414.19M and capital expenditures -7.49M, giving a free cash flow of -421.68M.

    Operating Cash Flow

    n/a
    		 -414.19M

    Capital Expenditures

    n/a
    		 -7.49M

    Free Cash Flow

    n/a
    		 -421.68M

    FCF Per Share

    n/a
    		 -4.66
    Full Cash Flow Statement

    Margins

    Gross margin is 86.3%, with operating and profit margins of -95.67% and -101.6%.

    Gross Margin

    n/a
    		 86.3%

    Operating Margin

    n/a
    		 -95.67%

    Pretax Margin

    n/a
    		 -101.31%

    Profit Margin

    n/a
    		 -101.6%

    EBITDA Margin

    n/a
    		 -83.72%

    EBIT Margin

    n/a
    		 -95.67%

    FCF Margin

    n/a
    		 -75.27%

    Dividends & Yields

    RARE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RARE is $81, which is 118.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $81

    Price Target Difference

    n/a
    		 118.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 13
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -3.07

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist